Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
28 03 2022
Historique:
received: 15 02 2022
revised: 12 03 2022
accepted: 25 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 14 4 2022
Statut: epublish

Résumé

Despite the high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, its full capacity is currently limited by the generation of dysfunctional CAR T cells. Senescent or exhausted CAR T cells possess poor targeting and effector functions, as well as impaired cell proliferation and persistence in vivo. Strategies to detect, prevent or reverse T cell exhaustion are therefore required in order to enhance the effectiveness of CAR T immunotherapy. Here we report that CD19 CAR T cells from non-responding patients with B cell malignancies show enrichment of CD8

Identifiants

pubmed: 35406703
pii: cells11071140
doi: 10.3390/cells11071140
pmc: PMC8997745
pii:
doi:

Substances chimiques

Antigens, CD19 0
Receptors, Chimeric Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Immunity. 2012 Dec 14;37(6):1130-44
pubmed: 23159438
Nature. 2022 Feb;602(7897):503-509
pubmed: 35110735
Sci Transl Med. 2017 Nov 22;9(417):
pubmed: 29167392
Nature. 2017 Mar 2;543(7643):113-117
pubmed: 28225754
Cancer Immunol Immunother. 2016 Apr;65(4):441-52
pubmed: 26850637
Cancer Res. 2018 Sep 1;78(17):5175
pubmed: 30115702
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Front Immunol. 2020 Feb 27;11:340
pubmed: 32174925
Blood. 2012 Oct 25;120(17):3455-65
pubmed: 22968455
Science. 2020 Feb 28;367(6481):
pubmed: 32029687
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Nat Med. 2015 Jun;21(6):581-90
pubmed: 25939063
J Leukoc Biol. 2017 Sep;102(3):601-615
pubmed: 28606939
Nat Med. 2020 Dec;26(12):1878-1887
pubmed: 33020644
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385732
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12410-12415
pubmed: 31152140
Cancer Cell. 2018 Apr 9;33(4):547-562
pubmed: 29634943
Blood Adv. 2021 Apr 27;5(8):2128-2136
pubmed: 33881465
Age (Dordr). 2009 Dec;31(4):285-91
pubmed: 19479342
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32152221
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
Nat Biotechnol. 2018 Oct;36(9):847-856
pubmed: 30102295
Front Immunol. 2013 Dec 19;4:455
pubmed: 24391639
Nat Rev Clin Oncol. 2018 Jan;15(1):31-46
pubmed: 28857075
Nature. 2017 Mar 9;543(7644):190-191
pubmed: 28225757
Immunity. 2016 Feb 16;44(2):380-90
pubmed: 26885860
Nat Med. 2010 Oct;16(10):1147-51
pubmed: 20890291
Nat Immunol. 2020 Dec;21(12):1552-1562
pubmed: 33046887
Nat Rev Immunol. 2012 Nov;12(11):749-61
pubmed: 23080391
Nat Rev Immunol. 2011 Apr;11(4):289-95
pubmed: 21436838
Blood Adv. 2019 Oct 8;3(19):2812-2815
pubmed: 31575532
Nat Immunol. 2003 Dec;4(12):1191-8
pubmed: 14625547
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
Nat Med. 2021 Aug;27(8):1410-1418
pubmed: 34385708
J Virol. 2003 Apr;77(8):4911-27
pubmed: 12663797
Immunity. 2016 Aug 16;45(2):389-401
pubmed: 27521269
J Exp Med. 1998 May 4;187(9):1383-93
pubmed: 9565631
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Sci Rep. 2017 Apr 7;7(1):737
pubmed: 28389661
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Nature. 2019 Dec;576(7786):293-300
pubmed: 31802004
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32606053
Nat Med. 2021 May;27(5):842-850
pubmed: 33888899
EMBO J. 2015 Aug 4;34(15):2008-24
pubmed: 26136212
Oncoimmunology. 2020 Apr 9;9(1):1744946
pubmed: 33457090
Nat Commun. 2020 Nov 19;11(1):5902
pubmed: 33214555
Nat Rev Immunol. 2003 Apr;3(4):269-79
pubmed: 12669018
Science. 2021 Apr 2;372(6537):
pubmed: 33795428
J Leukoc Biol. 2013 Jun;93(6):825-36
pubmed: 23440501
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167
pubmed: 31848460
Oncoimmunology. 2018 Oct 22;8(2):e1532762
pubmed: 30713785
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Science. 2016 Dec 2;354(6316):1160-1165
pubmed: 27789795
Blood. 2003 Apr 1;101(7):2711-20
pubmed: 12433688
Cell. 2016 Sep 8;166(6):1500-1511.e9
pubmed: 27610572
J Immunol. 1981 Sep;127(3):1024-9
pubmed: 6790607

Auteurs

Katia Beider (K)

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Orit Itzhaki (O)

Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, Tel Aviv 6997801, Israel.

Jacob Schachter (J)

Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, Tel Aviv 6997801, Israel.

Ania Hava Grushchenko-Polaq (AH)

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Valeria Voevoda-Dimenshtein (V)

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Evgenia Rosenberg (E)

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Olga Ostrovsky (O)

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Olivia Devillers (O)

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Ronnie Shapira Frommer (R)

Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, Tel Aviv 6997801, Israel.

Li-At Zeltzer (LA)

Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, Tel Aviv 6997801, Israel.

Amos Toren (A)

Center for Pediatric Cell Therapy, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Elad Jacoby (E)

Center for Pediatric Cell Therapy, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Avichai Shimoni (A)

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Abraham Avigdor (A)

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Arnon Nagler (A)

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv 6997801, Israel.

Michal J Besser (MJ)

Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, Tel Aviv 6997801, Israel.
Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH